Corgenix Named to Deloitte & Touche Colorado Technology Fast 50.

DENVER -- Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has been named to Deloitte's prestigious Fast 50 Program for Colorado. The program is a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the state by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations.

"Gaining recognition as a Fast 50 company demonstrates our focus on consistent and greater sales and profitability," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "We have moved several of our key products closer to market in the U.S. and internationally, and have prepared ourselves logistically for expected worldwide growth."

Corgenix ranks 43rd on this year's list. Kurt Randall of Deloitte Tax LLP explained that to rank on Deloitte's Colorado Technology Fast 50, companies must have phenomenal revenue growth over five years.

"Corgenix has proven to be one of the fast-growth success stories in Colorado, and we applaud their dedication to making their vision a reality," said Randall.

Corgenix has reached several significant milestones in the past year, including Food and Drug Administration (FDA) market clearance for its AspirinWorks([R]) laboratory test, submission to the FDA of its AtherOx(TM) products, and an 11 percent increase in sales for fiscal year 2007.

Launched in the United States in June 2007, the AspirinWorks test is now available nationwide through major medical reference laboratories, as well as direct to consumers through HealthCheckUSA (www.HealthCheckUSA.com). The test measures the effect of aspirin on blood platelets and allows physicians to individualize a patient's aspirin therapy.

To be considered, Technology Fast 50 entrants must: have operating revenues of at least $50,000 in 2002 and at least $5,000,000 in 2006; be headquartered in Colorado; own proprietary technology or proprietary intellectual property that contributes to a significant portion of its operating revenues, or devote a significant proportion of revenues to the research and development of technology.

Companies from the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.